HDAC9 and melanoma: Activation of bypassing mechanisms upon exposure of BRAFV600E A375 melanoma to PLX4720, sensitization to RTK and HDAC inhibitors (erlotinib, imatinib, and vorinostat), reduced cell survival, suppressed RB phosphorylation, increased apoptosis induction